News

Investigators aimed to characterize and evaluate the prevalence of sleep symptoms in patients with long COVID syndrome.

Factors including trust of information, fear, and resilience were related to insomnia and suicidal thoughts in healthcare workers, general population and outpatients.

Brett King, MD, PhD, reviews how the drug class has altered the state of chronic skin disease management in this year alone.

Why patience is key following the major FDA decision earlier this year.

An interview on the SDPA 2022 presentation of Dr. Woolery-Lloyd in which she discusses dermatoses affecting patients of color.

A discussion with Dr. Markowitz on her presentation from SDPA 2022, during which she described various gaps in knowledge on skin health and future innovations she hoped to see.

New long-term phase 3 data show adults and adolescents both improved measures of quality of life when treated with either of 2 doses of ruxolitinib cream.

Enhanced ellipsoid integrity, greater outer retinal thickness, and decreased GA were associated with increased BCVA gains with risuteganib.

A cohort study aimed to examine the risk of overdose when treating patients with benzodiazepines compared with alternative therapies for sleep disorders, specifically in young people.

The treatment is a broad-spectrum serine protease inhibitor that acts to neutralize digestive enzymes, can possibly reduce abdominal adhesions and accelerate the return of bowel function following gastrointestinal surgery.

The BLA was supported by positive data from 54 patients with hemophilia B in the pivotal phase 3 HOPE-B trial.

Only recent hospitalization and proton pump inhibitor use was deemed an independent risk factor for C difficile infections.

Neither intervention group demonstrated any significant improvements in intensity of chronic breathlessness after taking regular, low-dose, extended-release morphine.

The post-hoc analysis suggests reliable quantification of photoreceptor loss is an essential tool to evaluate therapeutic efficacy in slowing GA progression.

An interview with Dr. Markowitz on her presentation at SDPA 2022 presentation entitled ‘Skin of Color,’ regarding differentiating skin cancer from other conditions.

All ocular treatment-emergent adverse events were intravitreal injection related and mild or moderate in severity.

The incidence of NAFLD was 263.9 cases per 100,000 person-years in the infectious mononucleosis group, compared to 164.5 cases per 100,000 person-years in individuals without it.

An interview with Dr. Rosen regarding his SDPA 2022 presentation on dermatologic conditions with white spots that are often misdiagnosed as vitiligo.

HBsAg-positive women with adequate gestational weight again among pre-pregnancy normal-weight women had a higher risk of gestational diabetes mellitus than HBs-Ag-negative women.

A discussion with Dr. Rosen on one of his SPDA 2022 presentations, highlighting his reason for choosing the topic and exploring vitiligo misdiagnosis.

Findings from the ongoing LIBERTY AD OLE trial show the sustained long-term effect of the biologic therapy for eczema.

A discussion with Dr. Orozco on her SDPA 2022 presentation, discussing useful resources for physicians and PAs looking to get involved in the PAs Go Beyond campaign.

Two-thirds of eyes achieved a good visual outcome of 20/40 or better after cataract surgery among individuals with T2D.

In her SDPA 2022 presentation interview, Dr. Katta explores gaps in knowledge regarding the connection between skin disease and dietary health, as well as ways to address these concerns.

For NASH or NAFLD publications, the number of publications were on a continuous upward slope throughout the study period and finally surpassed HCV studies in 2020.

In the QUSAR study, 80% of patients treated with guselkumab achieved a clinical response.

The burden of sleep disorders is high among the transgender or gender-nonconforming population and this study evaluated the role of gender-affirming therapy on that relationship.

A faster rate of visual field progression was observed among 37 glaucomatous eyes treated with anti-VEGF for nAMD compared with a control group of 4304 eyes without anti-VEGF.